Catabasis Pharmaceuticals, Inc.
NASDAQ: CATB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jill Milne
- Employees
- 20
- Headquarters
- Boston, United States
- IPO year
- 2015
- Market cap
- $234.9M
- Website
- http://www.catabasis.com
Loading CATB…
Loading profile data…Frequently asked questions about CATB
What does Catabasis Pharmaceuticals, Inc. (CATB) do?
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), funct...
Where does CATB trade?
Catabasis Pharmaceuticals, Inc. (CATB) trades on the NASDAQ Global Market.
What sector is CATB in?
Catabasis Pharmaceuticals, Inc. (CATB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Catabasis Pharmaceuticals, Inc.?
Jill Milne is the chief executive officer of Catabasis Pharmaceuticals, Inc. (CATB).
Where is Catabasis Pharmaceuticals, Inc. headquartered?
Catabasis Pharmaceuticals, Inc. is headquartered in United States.
Does CATB pay a dividend?
Catabasis Pharmaceuticals, Inc. (CATB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CATB go public?
Catabasis Pharmaceuticals, Inc. (CATB) completed its initial public offering in 2015.